5

CLAIMS

- An orally, parenterally, rectally or transdermally administrable pharmaceutical composition for treating cardiovascular, thromboembolic, atherosclerotic, hyperlipidemic disorders and obesity and for decreasing appetite, comprising L-carnitine or an alkanoyl L-carnitine wherein the alkanoyl group is a straight or branched alkanoyl having 2-8, preferably 2-6, carbon atoms or a pharmacologically acceptable salt thereof, and hydroxycitric acid or pantothenic acid or derivative thereof as active ingredients, and a pharmacologically acceptable excipient.
- The composition of claim 1, wherein the alkanoyl group is selected from acetyl, propionyl, butyryl, valeryl and isovaleryl.
- The composition of claims 1 or 2, wherein the hydroxycitric acid derivative is a salt or ester thereof, a natural product or extract thereof containing same.
- 20 4. The composition of claims 1 or 2, wherein the pantothenic acid derivative is selected from the group comprising 4'-phosphopantothenate, 4'-phosphopantothenylcisteine, 4'-phosphopantotheine, pantotheine and pantethine.

- The composition of claim 3, wherein the hydroxycitric acid derivative is calcium hydroxycitrate.
- The composition of claim 3, wherein said extract is the extract
 from the fruits of Garcinia (Garcinia cambodia, Garcinia atroviridis,
 Garcinia indica, Garcinia citrin), or Malabar Tamarind or gorikapuli.
 - 7. The composition of anyone of the preceding claims, wherein the weight ratio between hydroxycitric acid or derivative thereof and L-carnitine, alkanoyl L-carnitine or pharmacologically acceptable salt thereof is from 1:1 to 1:100, and wherein the weight ratio between pantothenic acid or derivative thereof and L-carnitine, alkanoyl L-carnitine or pharmacologically acceptable salt thereof is from 10:1 to 1:100.
 - The composition of anyone of the preceding claims which further comprises vitamins, mineral salts, antioxidants and vegetal fibers.
- The composition of anyone of the preceding claims in a solid,
 semisolid, liquid, semiliquid, powder, granular or liposomic form,
 as tablets, capsules, granulates, powders and vials suitable for oral,
 parenteral, rectal or topic administration.

5

10. Co-ordinated use of L-carnitine or alkanoyl L-carnitine wherein the alkanoyl group has 2-8, preferably 2-6, carbon atoms, or pharmacologically acceptable salt thereof, and hydroxycitric acid or pantothenic acid or derivative thereof for treating cardiovascular, thromboembolic, atherosclerotic, hyperlipidaemic disorders and obesity, and for controlling and decreasing the appetite.